GlassScriptPhysician profile
Ross L Stutman
NPI 1528182557
$2,963.24
in general payments reported to CMS, 2019-2025
20 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $175 · 2021: $92.74 · 2022: $498 · 2023: $128 · 2024: $1,740 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $982 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700 · Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $981.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.00 |
| Food and Beverage | $296.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $981.67 | 2024 | |
| W. L. Gore & Associates, INC. | $700.00 | 2024 | Product In Development |
| Sientra, INC. | $322.34 | 2022-2023 | Sientra High Strength Cohesive Silicone Gel Breast Implant |
| Tela Bio, INC. | $260.72 | 2022 | |
| Lilly USA, LLC | $173.04 | 2019-2025 | Ebglyss, Taltz |
| Mentor Worldwide LLC | $89.88 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Genzyme Corporation | $54.28 | 2019-2020 | |
| Acelrx Pharmaceuticals, INC. | $49.70 | 2021 | |
| Dermira, INC. | $47.34 | 2019 | |
| Motiva USA, LLC | $38.16 | 2025 | |
| Sun Pharmaceutical Industries INC. | $33.01 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $29.05 | 2025 | |
| Biodermis LLC | $28.73 | 2025 | Pro-Sil, Biocorneum, Epi-Derm |
| Pfizer INC. | $26.91 | 2019 | |
| Revance Therapeutics, INC. | $25.55 | 2024 | Daxxify |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $23.56 | 2019 | |
| Kci USA, INC. | $21.93 | 2021 | |
| Biofrontera INC. | $21.11 | 2021 | |
| Acell, INC. | $19.51 | 2020 | |
| Integra Lifesciences Corporation | $16.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Stutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.